Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Outlook Therapeutics Inc OTLK

Healthcare Biotechnology
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD)... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OTLK)

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

GlobeNewswire November 6, 2024

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

GlobeNewswire October 17, 2024

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire September 16, 2024

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

GlobeNewswire September 13, 2024

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

GlobeNewswire September 4, 2024

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

GlobeNewswire August 14, 2024

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire August 12, 2024

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

GlobeNewswire August 7, 2024
View More News ››

Opinion & Analysis (NDAQ:OTLK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OTLK)

Outlook Therapeutics, Inc. (NASDAQ:OTLK): Poised for Potenti

http://beyondspx.com/2024/08/01/outlook-therapeutics-inc-nasdaqotlk-poised-for-potential-approval-and-launch-in-europe-advancing-towards...
MikeTester - August 2, 2024

Outlook Therapeutics&#xAE; Receives FDA Agreement Under Spec

BREAKING NEWS: $OTLK Outlook Therapeutics&#xAE; Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non...
whytestocks - January 23, 2024

PDUFA TOMORROW

FDA to make its decision tomorrow, all aboard if its approved. Highish shorts already on board so let's see a short squeeze at the...
InvrsContrarian - August 28, 2023

Completes Patient Enrollment for ONS-5010/LYTENAVA™ Study

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) https://www...
schoolofrock - November 3, 2020
View more Bullboard ››

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc. is a Canada-based exploration and mining company. The Company is focused on nickel, copper, and ...
View More »